Title:
GENE THERAPY
Document Type and Number:
Japanese Patent JP2023078376
Kind Code:
A
Abstract:
To provide cells for an improved cancer therapy.SOLUTION: Provided is a hematopoietic stem cell (HSC), a hematopoietic progenitor cell (HPC), a myeloid/monocyte-committed progenitor cell, a macrophage or a monocyte comprising a vector comprising at least one mir-130a and/or mir-126 target sequence operably linked to a nucleotide sequence encoding interferon-alpha (IFNα) for use in treating or preventing a cancer in a patient, the HSC, the HPC, the myeloid/monocyte-committed progenitor cell, the macrophage or the monocyte is used in combination with an immune checkpoint inhibitor and/or a tumor associated antigen (TAA)-specific T-cell.SELECTED DRAWING: None
Inventors:
LUIGI NALDINI
GIULIA ESCOBAR
BERNHARD RUDOLF GENTNER
ADELE MUCCI
GIULIA ESCOBAR
BERNHARD RUDOLF GENTNER
ADELE MUCCI
Application Number:
JP2023046113A
Publication Date:
June 06, 2023
Filing Date:
March 23, 2023
Export Citation:
Assignee:
OSPEDALE SAN RAFFAELE SRL
FONDZIONE TELETHON
FONDZIONE TELETHON
International Classes:
C12N5/10; A61K31/405; A61K35/12; A61K35/15; A61K35/17; A61K35/28; A61K38/19; A61K38/21; A61K39/395; A61K45/00; A61K48/00; A61P35/00; A61P35/02; A61P37/04; A61P43/00; C12N15/113
Attorney, Agent or Firm:
Patent Attorney Corporation Hiraki International Patent Office
Previous Patent: S1P1Compounds and methods of use thereof for modulating activity
Next Patent: drill guide assembly
Next Patent: drill guide assembly